Entrada Shares Sink After Duchenne Drug Trial Results
Entrada Therapeutics shares fell sharply on Thursday after its Duchenne muscular dystrophy drug ENTR-601-44 reported a 2.36 percentage point increase in dystrophin. This result significantly trailed analyst expectations of a 10 percent increase and lagged behind rival data from Avidity Biosciences.
Xurve View
Insights:
Xurve View
ENTRADA THERAPEUTICS INC shares fell more than 50% after its Duchenne muscular dystrophy drug failed to meet analyst efficacy targets. The trial reported a 2.36 percentage point increase in dystrophin protein from a 4% baseline, trailing the 10% minimum threshold set by William Blair analysts. This clinical shortfall places Entrada behind competitors in the race for exon-44 skipping treatments.
